Cardlytics, Inc. - Common Stock, par value $0.0001 (CDLX)

Q2 2021 13F Holders as of 30 Jun 2021

Type / Class
Equity / Common Stock, par value $0.0001
Shares outstanding
53,041,500
Number of holders
189
Total 13F shares, excl. options
31,402,934
Shares change
+920,086
Total reported value, excl. options
$3,990,653,437
Value change
+$126,270,154
Put/Call ratio
72%
Number of buys
95
Number of sells
-112
Price
$126.93

Significant Holders of Cardlytics, Inc. - Common Stock, par value $0.0001 (CDLX) as of Q2 2021

248 filings reported holding CDLX - Cardlytics, Inc. - Common Stock, par value $0.0001 as of Q2 2021.
Cardlytics, Inc. - Common Stock, par value $0.0001 (CDLX) has 189 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 31,402,934 shares of 53,041,500 outstanding shares and own 59.2% of the company stock.
Largest 10 shareholders include CAS Investment Partners, LLC (4,488,972 shares), WELLINGTON MANAGEMENT GROUP LLP (3,852,302 shares), VANGUARD GROUP INC (2,861,557 shares), BlackRock Inc. (2,511,295 shares), JPMORGAN CHASE & CO (1,774,390 shares), Alua Capital Management LP (1,244,259 shares), KPS Global Asset Management UK Ltd (1,126,830 shares), 683 Capital Management, LLC (911,092 shares), MORGAN STANLEY (753,293 shares), and Antipodean Advisors LLC (638,800 shares).
This table shows the top 189 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
Investor Option Weight % Change % Value $ * Price $ Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.